Skip to main content

Table 3 Summary of calculations fort individual coxibs, and all coxibs combined

From: Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk

  Annual event rate per 100 Annual event rate per 1000 Absolute risk frequency per year   Annual event rate per 100 Annual event rate per 1000 Absolute risk frequency per year
All coxib vs All NSAID Lumiracoxib vs NSAID
PUB     PUB    
NSAID 1.36 13.6 74 NSAID 1.21 12.1 83
All coxib 0.56 5.6 179 Lumiracoxib 0.46 4.6 217
Difference   8.0 125 Difference   7.5 133
APTC     APTC    
NSAID 0.89 8.9 112 NSAID 0.82 8.2 122
All coxib 0.97 9.7 103 Lumiracoxib 0.92 9.2 109
Difference   -0.8 -1250 Difference   -1.0 -1000
Celecoxib vs NSAID Valdecoxib vs NSAID
PUB     PUB    
NSAID 2.09 20.9 48 NSAID 1.95 19.5 51
Celecoxib 0.93 9.3 108 Valdecoxib 0.68 6.8 147
Difference   11.6 86 Difference   12.7 79
APTC     APTC    
NSAID 1.20 12.0 83 NSAID 1.97 19.7 51
Celecoxib 1.00 10 100 Valdecoxib 1.27 12.7 79
Difference   2.0 500 Difference   7.0 143
Rofecoxib vs NSAID Etoricoxib vs NSAID
PUB     PUB    
NSAID 0.90 9.0 111 NSAID 1.03 10.3 97
Rofecoxib 0.33 3.3 303 Etoricoxib 0.47 4.7 213
Difference   5.7 175 Difference   5.6 179
APTC     APTC    
NSAID 0.87 8.7 115 NSAID 0.80 8.0 125
Rofecoxib 1.19 11.9 84 Etoricoxib 0.91 9.1 110
Difference   -3.2 -313 Difference   -1.1 -909
  1. PUB – perforations, ulcers, bleeds; APTC – Antiplatelet Triallists Collaboration outcome of fatal and nonfatal heart attack or stroke, and cardiovascular death. In these calculations, the annualised event rates have been converted for simplicity to event rates per 1000 patients, and absolute event frequency per year calculated from that. Differences between NSAID and coxibs were calculated, and the absolute risk difference frequency calculated. This is equivalent to a number needed to prevent one event if positive, and number needed to harm if negative, for one year of treatment of coxib rather than an NSAID